Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIDE AMD: Systemic VEGF Dynamics of Ranibizumab vs Aflibercept in wAMD
NCT02257632Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Mar 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in exudative macular degeneration, sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02257632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257632.